Non-variceal upper gastrointestinal bleeding: Rescue treatment with a modified cyanoacrylate

AIM To evaluate the safety and efficacy of a modified cyanoacrylate [N-butyl-2-cyanoacrylate associated with methacryloxysulfolane(NBCA + MS)] to treat nonvariceal upper gastrointestinal bleeding(NV-UGIB).METHODS In our retrospective study we took into account 579 out of 1177 patients receiving endo...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG Vol. 22; no. 48; pp. 10609 - 10616
Main Authors: Grassia, Roberto, Capone, Pietro, Iiritano, Elena, Vjero, Katerina, Cereatti, Fabrizio, Martinotti, Mario, Rozzi, Gabriele, Buffoli, Federico
Format: Journal Article
Language:English
Published: United States Baishideng Publishing Group Inc 28-12-2016
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM To evaluate the safety and efficacy of a modified cyanoacrylate [N-butyl-2-cyanoacrylate associated with methacryloxysulfolane(NBCA + MS)] to treat nonvariceal upper gastrointestinal bleeding(NV-UGIB).METHODS In our retrospective study we took into account 579 out of 1177 patients receiving endoscopic treatment for NV-UGIB admitted to our institution from 2008 to 2015; the remaining 598 patients were treated with other treatments. Initial hemostasis was not achieved in 45 of 579 patients; early rebleeding occurred in 12 of 579 patients. Thirty-three patients were treated with modified cyanoacrylate: 27 patients had duodenal, gastric or anastomotic ulcers, 3 had post-mucosectomy bleeding, 2 had Dieulafoy’s lesions, and 1 had duodenal diverticular bleeding.RESULTS Of the 45 patients treated endoscopically without initialhemostasis or with early rebleeding, 33(76.7%) were treated with modified cyanoacrylate glue, 16(37.2%) underwent surgery, and 3(7.0%) were treated with selective transarterial embolization. The mean age of patients treated with NBCA + MS(23 males and 10 females) was 74.5 years. Modified cyanoacrylate was used in 24 patients during the first endoscopy and in 9 patients experiencing rebleeding. Overall, hemostasis was achieved in 26 of 33 patients(78.8%): 19 out of 24(79.2%) during the first endoscopy and in 7 out of 9(77.8%) among early rebleeders. Two patients(22.2%) not responding to cyanoacrylate treatment were treated with surgery or transarterial embolization. One patient had early rebleeding after treatment with cyanoacrylate. No late rebleeding during the follow-up or complications related to the glue injection were recorded.CONCLUSION Modified cyanoacrylate solved definitively NV-UGIB after failure of conventional treatment. Some reported life-threatening adverse events with other formulations, advise to use it as last option.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Telephone: +39-372-405255 Fax: +39-372-405254
Author contributions: Grassia R and Buffoli F designed the research and analyzed the data; Grassia R, Capone P, Iiritano E, Vjero K, Cereatti F, Martinotti M, Rozzi G and Buffoli F performed the research; Grassia R wrote the paper.
Correspondence to: Roberto Grassia, MD, Dirigente Medico I livello, Digestive Endoscopy and Gastroenterology Unit, “ASST di Cremona”, Viale Concordia n 1, 26100 Cremona, Italy. robertograssia@yahoo.it
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v22.i48.10609